{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:26:39Z","timestamp":1793697999966,"version":"4.5.1"},"reference-count":94,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clml.2026.07.012","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:38:36Z","timestamp":1784936316000},"page":"e1147-e1159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions | Predictive Markers for Ruxolitinib in Myelofibrosis"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-5668","authenticated-orcid":false,"given":"Francesca","family":"Palandri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Branzanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.clml.2026.07.012_bib0001","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.2022017423","article-title":"Myelofibrosis","volume":"141","author":"Passamonti","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.012_bib0002","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.70141","article-title":"Risk of transformation to acute myeloid leukaemia and myelodysplastic syndromes in patients with myeloproliferative neoplasms over attained age and time since diagnosis: a nationwide cohort study","author":"Batyrbekova","year":"2026","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.clml.2026.07.012_bib0003","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"Suppl 4","key":"10.1016\/j.clml.2026.07.012_bib0004","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ajh.27658","article-title":"Targeted therapies in myelofibrosis: present landscape, ongoing studies, and future perspectives","volume":"100","author":"Loscocco","year":"2025","journal-title":"Am J Hematol"},{"issue":"16","key":"10.1016\/j.clml.2026.07.012_bib0005","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood.2022017416","article-title":"Biology and therapeutic targeting of molecular mechanisms in MPNs","volume":"141","author":"How","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.07.012_bib0006","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2026.07.012_bib0007","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2026.07.012_bib0008","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.clml.2026.07.012_bib0009","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2026.07.012_bib0010","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.012_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.683401","article-title":"Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms","volume":"12","author":"Fisher","year":"2021","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.clml.2026.07.012_bib0012","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/cncr.34707","article-title":"Early intervention in myelofibrosis and impact on outcomes: a pooled analysis of the COMFORT-I and COMFORT-II studies","volume":"129","author":"Verstovsek","year":"2023","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.clml.2026.07.012_bib0013","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.clml.2026.07.012_bib0014","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2026.07.012_bib0015","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"45","key":"10.1016\/j.clml.2026.07.012_bib0016","doi-asserted-by":"crossref","first-page":"79073","DOI":"10.18632\/oncotarget.18674","article-title":"Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis","volume":"8","author":"Palandri","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2026.07.012_bib0017","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35489","article-title":"Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: the RUX-MF real-world study","author":"Palandri","year":"2024","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.clml.2026.07.012_bib0018","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clml.2026.07.012_bib0019","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","article-title":"Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"97","author":"Kuykendall","year":"2018","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.clml.2026.07.012_bib0020","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1016\/j.clml.2025.02.015","article-title":"Disease phenotype significantly influences the outcome after discontinuation of ruxolitinib in chronic phase myelofibrosis","volume":"25","author":"Palandri","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.07.012_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2025.107719","article-title":"Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: the Italian RUX-MF multicenter study","volume":"154","author":"Palandri","year":"2025","journal-title":"Leuk Res"},{"issue":"13","key":"10.1016\/j.clml.2026.07.012_bib0022","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2026.07.012_bib0023","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (international working group for myeloproliferative neoplasms research and treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2026.07.012_bib0024","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2026.07.012_bib0025","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.07.012_bib0026","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025031366","article-title":"Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis","author":"Mora","year":"2026","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2026.07.012_bib0027","doi-asserted-by":"crossref","first-page":"e735","DOI":"10.1016\/S2352-3026(23)00174-6","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study","volume":"10","author":"Gerds","year":"2023","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.clml.2026.07.012_bib0028","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.clml.2026.07.012_bib0029","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.clml.2026.07.012_bib0030","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/cncr.34722","article-title":"Ruxolitinib in cytopenic myelofibrosis: response, toxicity, drug discontinuation, and outcome","volume":"129","author":"Palandri","year":"2023","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clml.2026.07.012_bib0031","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2026.2628361","article-title":"Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survival","volume":"67","author":"Kuykendall","year":"2026","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.clml.2026.07.012_bib0032","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35156","article-title":"Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy","volume":"130","author":"Palandri","year":"2024","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clml.2026.07.012_bib0033","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.16462","article-title":"Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts","volume":"189","author":"Al-Ali","year":"2020","journal-title":"Br J Haematol"},{"issue":"34","key":"10.1016\/j.clml.2026.07.012_bib0034","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-na\u00efve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clml.2026.07.012_bib0035","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2026.07.012_bib0036","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.07.012_bib0037","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/OTT.S53348","article-title":"Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes","volume":"7","author":"Verstovsek","year":"2013","journal-title":"Onco Targets Ther"},{"issue":"4","key":"10.1016\/j.clml.2026.07.012_bib0038","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70320","article-title":"Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis","volume":"132","author":"Palandri","year":"2026","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.clml.2026.07.012_bib0039","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2026.07.012_bib0040","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"Mascarenhas","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2026.07.012_bib0041","unstructured":"Jakavi | European Medicines Agency (EMA). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jakavi. Accessed: June 19, 2026."},{"issue":"5","key":"10.1016\/j.clml.2026.07.012_bib0042","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3324\/haematol.2018.204602","article-title":"EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis","volume":"104","author":"Vannucchi","year":"2019","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.clml.2026.07.012_bib0043","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1038\/s41375-021-01396-x","article-title":"Correction: efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study (Leukemia, (2021), 35, 12, (3455-3465), 10.1038\/s41375-021-01261-x)","volume":"35","author":"Cervantes","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.07.012_bib0044","article-title":"The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: a prospective real-world study on AIFA monitoring registries","author":"Breccia","year":"2024","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2026.07.012_bib0045","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/10428194.2020.1845334","article-title":"Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study","volume":"62","author":"Gupta","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.clml.2026.07.012_bib0046","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35801","article-title":"Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: interim results of the Italian observational study (ROMEI)","volume":"131","author":"Breccia","year":"2025","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clml.2026.07.012_bib0047","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/ejh.70005","article-title":"Final results from a large, non-interventional, phase 4 study of ruxolitinib for the treatment of myelofibrosis in clinical routine","volume":"115","author":"Koschmieder","year":"2025","journal-title":"Eur J Haematol"},{"issue":"17","key":"10.1016\/j.clml.2026.07.012_bib0048","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70062","article-title":"Revised \u201ciRR6\u201d model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib","volume":"131","author":"Palandri","year":"2025","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.clml.2026.07.012_bib0049","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00277-024-05704-0","article-title":"Ruxolitinib adherence in myelofibrosis and polycythemia vera: the \u201cRAMP\u201d Italian multicenter prospective study","volume":"103","author":"Palandri","year":"2024","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2026.07.012_bib0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/10428194.2021.1969388","article-title":"Adherence to ruxolitinib, an oral JAK1\/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI)","volume":"63","author":"Guglielmelli","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.clml.2026.07.012_bib0051","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.3390\/cancers15102859","article-title":"Benefit of early ruxolitinib initiation regardless of fibrosis grade in patients with primary myelofibrosis: a post hoc analysis of the single-arm phase 3b JUMP study","volume":"15","author":"Palandri","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.clml.2026.07.012_bib0052","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","article-title":"Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Mesa","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.07.012_bib0053","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-60019-6","article-title":"Efficacy of JAK1\/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling","volume":"16","author":"Gorantla","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.clml.2026.07.012_bib0054","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41375-018-0159-0","article-title":"ASXL1\/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF","volume":"33","author":"Triviai","year":"2019","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.clml.2026.07.012_bib0055","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/cncr.34216","article-title":"Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis","volume":"128","author":"Palandri","year":"2022","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.clml.2026.07.012_bib0056","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1002\/cncr.33094","article-title":"Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era","volume":"126","author":"Masarova","year":"2020","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clml.2026.07.012_bib0057","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ajh.24978","article-title":"Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.clml.2026.07.012_bib0058","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2013-11-536557","article-title":"Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study","volume":"123","author":"Guglielmelli","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.07.012_bib0059","article-title":"Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy","volume":"104","author":"Palandri","year":"2025","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.clml.2026.07.012_bib0060","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12185-021-03180-0","article-title":"MPL overexpression induces a high level of mutant-CALR\/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations","volume":"114","author":"Yasuda","year":"2021","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1016\/j.clml.2026.07.012_bib0061","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2026.07.012_bib0062","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2026.07.012_bib0063","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0152-x","article-title":"Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea","volume":"8","author":"Pacilli","year":"2018","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.clml.2026.07.012_bib0064","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.07.012_bib0065","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.27136","article-title":"The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70\/plus\/plus v2.0) for primary myelofibrosis","volume":"99","author":"Loscocco","year":"2024","journal-title":"Am J Hematol"},{"issue":"20","key":"10.1016\/j.clml.2026.07.012_bib0066","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2017009530","article-title":"Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1\/2 inhibitor therapy","volume":"1","author":"Spiegel","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2026.07.012_bib0067","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41375-024-02422-4","article-title":"Synergistic effect of concurrent high molecular risk mutations and lower JAK2 mutant variant allele frequencies on prognosis in patients with myelofibrosis-insights from a multicenter study","volume":"39","author":"Wang","year":"2025","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.clml.2026.07.012_bib0068","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1182\/bloodadvances.2020002175","article-title":"RAS\/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features","volume":"4","author":"Coltro","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2026.07.012_bib0069","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-019-0603-9","article-title":"Prognostic impact of RAS-pathway mutations in patients with myelofibrosis","volume":"34","author":"Santos","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2026.07.012_bib0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-60884-1","article-title":"JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms","volume":"16","author":"Maslah","year":"2025","journal-title":"Nat Commun"},{"issue":"357","key":"10.1016\/j.clml.2026.07.012_bib0071","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2005301","article-title":"RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis","volume":"7","author":"Winter","year":"2014","journal-title":"Sci Signal"},{"issue":"4","key":"10.1016\/j.clml.2026.07.012_bib0072","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1172\/JCI98785","article-title":"Targeting compensatory MEK\/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms","volume":"129","author":"Stivala","year":"2019","journal-title":"J Clin Invest"},{"issue":"22","key":"10.1016\/j.clml.2026.07.012_bib0073","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1002\/cncr.34986","article-title":"New era for myelofibrosis treatment with novel agents beyond Janus kinase-inhibitor monotherapy: focus on clinical development of BCL-XL\/BCL-2 inhibition with navitoclax","volume":"129","author":"Pemmaraju","year":"2023","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clml.2026.07.012_bib0074","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s40364-025-00865-0","article-title":"Combinatorial BCL2\/BCL2L1 expression predicts clinical response to ruxolitinib in myelofibrosis","volume":"13","author":"Coltro","year":"2025","journal-title":"Biomark Res"},{"issue":"5","key":"10.1016\/j.clml.2026.07.012_bib0075","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41375-018-0018-z","article-title":"Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2026.07.012_bib0076","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.07.012_bib0077","series-title":"NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms. Version 2.2026","year":"2026"},{"issue":"6","key":"10.1016\/j.clml.2026.07.012_bib0078","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","article-title":"A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis","volume":"6","author":"Maffioli","year":"2022","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.clml.2026.07.012_bib0079","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1182\/bloodadvances.2022008158","article-title":"RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort","volume":"6","author":"Scalzulli","year":"2022","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.clml.2026.07.012_bib0080","doi-asserted-by":"crossref","first-page":"7418","DOI":"10.3390\/jcm11247418","article-title":"Prediction of survival and prognosis migration from gold-standard scores in myelofibrosis patients treated with ruxolitinib applying the RR6 prognostic model in a monocentric real-life setting","volume":"11","author":"Duminuco","year":"2022","journal-title":"J Clin Med"},{"issue":"20","key":"10.1016\/j.clml.2026.07.012_bib0081","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15205027","article-title":"A prognostic model to predict ruxolitinib discontinuation and death in patients with myelofibrosis","volume":"15","author":"Palandri","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clml.2026.07.012_bib0082","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-42101-z","article-title":"Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis","volume":"14","author":"Wildschut","year":"2023","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.clml.2026.07.012_bib0083","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.molcel.2020.04.008","article-title":"Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets","volume":"78","author":"Psaila","year":"2020","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.clml.2026.07.012_bib0084","first-page":"73","article-title":"Single-cell analysis based dissection of clonality in myelofibrosis","volume":"11","author":"Mylonas","year":"2020","journal-title":"Nature Communications 2020 11:1"},{"issue":"10","key":"10.1016\/j.clml.2026.07.012_bib0085","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2026.07.012_bib0086","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","article-title":"Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NF\u03baB signaling","volume":"33","author":"Fisher","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.07.012_bib0087","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025030094","article-title":"A stem and progenitor cell-derived gene expression signature is prognostic for survival in myelofibrosis","author":"Medeiros","year":"2026","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.07.012_bib0088","doi-asserted-by":"crossref","first-page":"e541","DOI":"10.1016\/S2352-3026(20)30121-6","article-title":"Machine learning in haematological malignancies","volume":"7","author":"Radakovich","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2026.07.012_bib0089","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.70231","article-title":"Artificial intelligence for risk assessment and outcome prediction in malignant haematology","volume":"208","author":"Eckardt","year":"2026","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1016\/j.clml.2026.07.012_bib0090","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood.2024027287","article-title":"Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis","volume":"145","author":"Hern\u00e1ndez-Boluda","year":"2025","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2026.07.012_bib0091","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1182\/blood.2025029876","article-title":"Artificial intelligence in hematology","volume":"146","author":"Nazha","year":"2025","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2026.07.012_bib0092","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood.2023022415","article-title":"How I individualize selection of JAK inhibitors for patients with myelofibrosis","volume":"145","author":"Masarova","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2026.07.012_bib0093","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41591-025-03572-3","article-title":"Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial","volume":"31","author":"Rampal","year":"2025","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.clml.2026.07.012_bib0094","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.21.02188","article-title":"Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy","volume":"40","author":"Harrison","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502600217X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502600217X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:36:13Z","timestamp":1793694973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502600217X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":94,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S215226502600217X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Predictive Markers for Ruxolitinib in Myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}